Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: A comparison with bromocriptine

European Journal of Endocrinology

Volumn 138, Issue 3, 1998, Pages 286-293

  De Rosa, Michele ^a   Colao, Annamaria ^a   Di Sarno, Antonella ^a   Ferone, Diego ^a   Landi, Maria Luisa ^a   Zarrilli, Stefano ^a   Paesano, Luigi ^a   Merola, Bartolomeo ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; BROMOCRIPTINE; CABERGOLINE; FOLLITROPIN; LUTEINIZING HORMONE; PROLACTIN; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG TOLERABILITY; GALACTORRHEA; GONAD FUNCTION; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; LIBIDO; MALE; MALE INFERTILITY; PATIENT COMPLIANCE; PENIS ERECTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SEMINAL PLASMA; SEXUAL FUNCTION; SPERMATOZOON COUNT; SPERMATOZOON MOTILITY; TESTOSTERONE BLOOD LEVEL;

ADULT; BROMOCRIPTINE; COHORT STUDIES; DOPAMINE AGONISTS; ERGOLINES; FOLLOW-UP STUDIES; HORMONES; HUMANS; HYPERPROLACTINEMIA; LIBIDO; MALE; PENILE ERECTION; PROLACTIN; SEMEN; TIME FACTORS;

EID: 0031958285     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1380286     Document Type: Article

References (28)

1. Carter JN, Tyson JE, Tolis G, Van Vliet S, Faiman C & Friesen HG. Prolactin-secreting tumors and hypogonadism in 22 men. New England Journal of Medicine 1978 299 847-852.
2. Segal S, Yaffe H, Laufer N & Ben-David M. Male hyperprolactinemia: effects in fertility. Fertility and Sterility 1979 32 556-561.
3. Thorner MO, McNeilly AS, Hagan C & Besser GM. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. British Medical Journal 1974 2 419-422.
4. Ambrosi B, Bara R, Travaglini P, Weber G, Beck-Peccoz P, Rondena M et al. Short communication: Study of the effects of bromocriptine on sexual impotence. Clinical Endocrinology 1977 7 417-421.
5. Hovatta O, Koskimies AI, Ranta T, Stenman UH & Seppala M. Bromocriptine treatment of oligospermia: a double blind study. Clinical Endocrinology 1979 11 377-382.
6. Vance M, Evans W & Thorner M. Bromocriptine. Annals of Internal Medicine 1984 100 78-91.
7. Schettini G, Lombardi G, Merola B, Colao A, Miletto P, Caruso E et al. Rapid and long-lasting suppression on prolactin secretion and shrinkage of prolactinomas with improved tolerability after injection of long-action repeatable form of bromocriptine (Parlodel LAR). Clinical Endocrinology 1990 33 161-169.
8. Merola B, Colao A, Caruso E, Sarnacchiaro F, Lancranjan I, Lombardi G et al. Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia. Journal of Endocrinological Investigation 1992 15 173-176.
9. Colao A, Merola B, Sarnacchiaro F, Di Sarno A, Landi ML, Marzullo P et al. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. Hormone Research 1995 44 222-228.
10. Colao A, De Rosa M, Sarnacchiaro F, Di Sarno A, Landi ML, Iervolino E et al. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. European Journal of Endocrinology 1996 135 548-552.
11. Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Paracchi A et al. Long-lasting prolactin lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. Journal of Clinical Endocrinology and Metabolism 1986 63 941-945.
12. Ciccarelli E, Giusti M, Miola A, Potenzoni F, Sghedoni D, Camanni F et al. Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. Journal of Clinical Endocrinology and Metabolism 1989 69 725-728.
13. Ferrari C, Mattei A, Melis GB, Paracchi A, Muratori M, Faglia G et al. Cabergoline: long-acting oral treatment of hyperprolactinemia disorders. Journal of Clinical Endocrinology and Metabolism 1989 69 1201-1206.
14. Webster J, Piscitelli G, Polli A, D'Alberton A, Falsetti L, Ferrari C et al. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinemia: a placebo controlled, double blind, multicentric study. Clinical Endocrinology 1992 37 534-541.
15. Webster J, Piscitelli G, Polli A, Ferrari C, Ismail I, Scanlon MF, for the Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. New England Journal of Medicine 1994 331 904-909.
16. Biller BMK, Molitch ME, Vance ML, Baker K, Cannistraro B, Davis KR et al. Treatment of prolactin-secreting macroadenoma with once-weekly dopamine agonist cabergoline. Journal of Clinical Endocrinology and Metabolism 1996 81 2338-2343.
17. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Journal of Clinical Endocrinology and Metabolism 1997 82 876-883.
18. World Health Organization. Laboratory Manual for the Examination of Human Semen and Semen-Cervical Mucus Interaction. World Health Organization, Cambridge University Press, 1993.
19. De Rosa M, Amalfi B, Mennitti M, Zarrilli S & Lombardi G. The usefulness of new tests in the evaluation of the ejaculate. In Progress in Reproductive Medicine. Diagnosing Male Infertility, vol 15, pp 19-26. Eds GM Colpi & D Pozza. Basel: Karger.
20. Bradley WE, Timm GW, Gallagher JM & Johnson BK. New method for continuous measurement of nocturnal penile tumescence and rigidity. Urology 1985 26 4-8.
21. Bancroft J & Malone N. The clinical assessment ot erectile dysfunction: a comparison of nocturnal penile tumescence monitoring and intracavernosal injections. International Journal of Impotence Research 1995 7 123-126.
22. 3H]N-n-propylnorapomorphine. European Journal of Pharmacology 1990 187 399-408.
23. Hondo E, Kurohmaru M, Sakai S, Ogawa K & Hayashi Y. Prolactin receptor expression in rat spermatogenic cells. Biology of Reproduction 1995 52 1284-1290.
24. Bartke AJ. Effects of prolactin and luteinizing hormone on the cholesterol stores in the mouse testis. Journal of Endocrinology 1971 49 317-320.
25. 1-14C]acetate into testosterone and cholesterol by testes from hypophysectomized rats in vitro. Journal of Endocrinology 1972 53 223-226.
26. Park SK, Keenan MW & Selmanoff M. Graded hyperprolachnemia first suppresses LH pulse frequency and then pulse amplitude in castrated male rats. Neuroendocrinology. 1993 58 448-453.
27. Bohnet HG, Dahlen HG, Wuttke W & Schneider HPG. Hyperprolactinemic anovulatory syndrome. Journal of Clinical Endocrinology and Metabolism 1976 42 132-143.
28. Delgrange E & Donckier J. Gonadal dysfunction in males with prolactinoma: from functional modification to irreversible damage? European Journal of Endocrinology 1997 136 630.